How Pattern Hair Loss Differs Between Men and Women matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
A friend of mine, Dave, sat across from me at a pub in Birmingham last autumn and pulled up a photo on his phone. It was a top-down shot of his own scalp, taken in his bathroom under the overhead light. “My wife took this,” he said. “I didn’t realize it looked like that.” Dave is 34. He’d been noticing his hairline creep back since his late twenties, but the crown thinning caught him off guard. His GP had shrugged and told him it was “just genetics.” Which is technically true. It’s also not very helpful.
The truth is that androgenetic alopecia is one of the most studied conditions in dermatology, with a classification framework that’s been in use for over 70 years and a treatment evidence base that’s surprisingly solid. But most people experiencing it have never heard of the Norwood scale, the Ludwig scale, or follicular miniaturization. They just know their hair looks different than it did five years ago. This piece is meant to close that gap: the same clinical reasoning a dermatologist would walk through, minus the copay.
The Scales That Dermatologists Actually Use
James Hamilton published the original framework for male pattern hair loss in 1951 in the Annals of the New York Academy of Sciences. His key observation was elegantly simple: men castrated before puberty never developed the characteristic recession and crown thinning of androgenetic alopecia. Androgens, specifically, were the driver.
O’Tar Norwood expanded Hamilton’s work in 1975 (Southern Medical Journal), stretching the original three-stage system into seven stages with variant subtypes. The Type A variant, where loss marches straight back from the front rather than following the classic bitemporal-plus-vertex pattern, is one that trips people up. They don’t see the “horseshoe” forming and assume they’re fine.
For women, it’s a different picture entirely. Female pattern hair loss (FPHL) typically presents as diffuse thinning across the crown with preservation of the frontal hairline. The Ludwig scale and the Savin scale capture this pattern, while the more recent BASP (basic and specific) classification proposed in 2007 attempts to unify both sexes under one system. In practice, most clinics still default to Norwood for men and Ludwig for women, because they’re quick and clinicians agree on what they’re seeing. For a detailed visual walkthrough of how these stages progress, this hair loss staging guide walks through the clinical grading with photographic examples.
The boring truth is that these scales don’t tell you what to do. They tell you where you are. The treatment plan depends on where you are relative to where you want to be, which is a different conversation entirely.
What DHT Actually Does to a Hair Follicle
The biology here is well understood and fairly elegant in a destructive sort of way. Testosterone gets converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is a much more potent androgen. In follicles that are genetically sensitive to it (and not all follicles are, which is why the back and sides of your head keep their hair), DHT binds to the androgen receptor in the dermal papilla and starts a slow degradation process.
Each successive hair cycle gets shorter. The anagen (growth) phase shrinks. The telogen (resting) phase stretches out. The follicle itself physically miniaturizes. Hairs that used to grow thick, pigmented, and long become thin, short, and eventually vellus, those wispy colorless hairs you can only see in the right light. That’s miniaturization in a nutshell.
The genetics are polygenic, meaning there’s no single “baldness gene.” The androgen receptor gene on the X chromosome is one contributor (hence the old wisdom about checking your mother’s father), but autosomal loci from the paternal side matter too. Family history gives you a rough directional signal. It doesn’t give you a timeline.
The Dermatology Workup Most People Skip
Here’s where things diverge from what most men actually do, which is Google “am I going bald,” look at some pictures, and either panic or ignore it. A structured dermatologic evaluation looks quite different.
History comes first. When did the loss start? Is it progressive or episodic? Any new medications, crash diets, major stressors in the past three to six months? Family pattern on both sides?
Then comes trichoscopy, which is dermoscopy applied to the scalp. Under magnification, androgenetic alopecia shows characteristic hair shaft diameter variability (caliber variability of 20% or greater), yellow dots representing empty follicular ostia, and reduced follicular unit density in affected zones with a preserved occipital donor area. These findings help distinguish pattern loss from telogen effluvium, alopecia areata, and scarring alopecias, all of which look quite different under the scope.
Lab work is selective, not blanket. The American Academy of Dermatology doesn’t recommend routine androgen panels in men with classic pattern loss because the diagnosis is clinical. But ferritin, TSH, vitamin D, and a CBC are reasonable when diffuse shedding or atypical presentation is involved, particularly in women where FPHL and telogen effluvium frequently overlap.
Standardized photography (front, top, sides, back, consistent distance and lighting) is the unglamorous workhorse of tracking. Without it, you’re relying on memory and bathroom-mirror impressions, which are unreliable in both directions.
What Actually Works, Ranked by Evidence
I’ll be direct: the earlier you start, the better your outcomes. That’s not marketing. It’s the pharmacology. You can’t regrow follicles that have already fully miniaturized.
Oral finasteride (1 mg daily) has the deepest evidence base. The pivotal five-year randomized trial published in JAAD in 2002 showed sustained hair count improvements versus placebo. Sexual side effects (decreased libido, erectile dysfunction) are reported by a small percentage of users in controlled trials and are generally reversible on discontinuation. The risk-benefit conversation is real, but it should be an actual conversation with a clinician, not a Reddit thread.
Topical minoxidil (5%, twice daily) is FDA-approved and available over the counter. The mechanism isn’t fully pinned down but involves potassium channel opening, local vasodilation, and a direct follicular effect that prolongs anagen. Visible results typically show up at three to six months. Foam and solution are clinically equivalent; foam causes less scalp irritation in some users.
Low-dose oral minoxidil (0.25 to 5 mg daily) gained traction after Vañó-Galván et al. published their 1,404-patient safety study in JAAD in 2021. At low doses, the side-effect profile is more manageable than the original cardiovascular formulation. Hypertrichosis (unwanted body hair growth) and periorbital edema are the most commonly reported issues.
Dutasteride inhibits both type I and type II 5-alpha reductase isoforms, producing larger DHT reductions than finasteride. Head-to-head trials (Olsen et al., JAAD, 2006) have shown larger hair density improvements. It’s approved for benign prostatic hypertrophy, not hair loss, so its use here is off-label.
PRP and microneedling sit in the “reasonable adjunct” category. JAMA Dermatology has published several smaller randomized trials with positive but variable results (Gentile & Garcovich, 2020). They’re additions to medical therapy, not replacements for it.
Hair transplantation (FUE or FUT) is the only option that physically moves follicles from the resistant donor zone to the thinning recipient area. It works best when the loss pattern has stabilized, donor capacity is adequate, and expectations are calibrated. In the US, FUE runs roughly $4 to $10 per graft; a typical 2,500 to 3,500 graft case costs $10,000 to $35,000. In Turkey, the same graft count runs $2,000 to $5,000, reflecting labor cost differences more than quality differences, though quality varies enormously between clinics there.
The Money Part
Generic finasteride: $10 to $25/month at US pharmacies with discount cards, sometimes $5 to $15 through telehealth platforms. Branded Propecia: $70 to $90/month with no documented clinical advantage. That price premium is paying for a name.
Generic topical minoxidil: $10 to $30/month. Branded Rogaine: roughly double.
Low-dose oral minoxidil: often under $15/month in generic form. The bigger cost is the prescribing visit ($50 to $150 through telehealth, or covered under insurance if you’re seeing a derm anyway).
PRP: $500 to $1,500 per session, three to four sessions the first year, maintenance thereafter. First-year PRP costs can easily match or exceed a full year of combination medical therapy.
Insurance generally classifies all of this as cosmetic. HSAs and FSAs may cover prescribed medications and office visits, but typically not surgical procedures.
Lifestyle Factors (What’s Real, What’s Noise)
Pattern hair loss is genetically determined. Full stop. But several factors influence the pace and severity.
Smoking accelerates loss through microvascular damage to the dermal papilla and oxidative stress. Cross-sectional data consistently shows higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a clinical concern) contributes through telogen effluvium. Repleting iron in deficient patients reduces shedding. Supplementing iron-replete patients does nothing.
Severe acute stress can trigger telogen effluvium two to three months after the event, typically resolving within six to nine months once the stressor passes. It can, however, unmask underlying pattern loss that was previously subclinical.
Anabolic steroid use accelerates pattern loss in genetically susceptible men through supraphysiologic androgen exposure, and the effects may not fully reverse after stopping.
Crash diets, very low protein intake, and rapid weight loss reliably produce telogen effluvium. Modest dietary improvements beyond fixing specific deficiencies don’t produce visible hair benefits. If someone is selling you a “hair growth superfood,” they’re selling you something.
When You Need an In-Person Dermatologist
Self-management is reasonable in many cases. But certain presentations need a real exam, not a telehealth screen.
Sudden, diffuse shedding within the past six months suggests telogen effluvium and needs a workup for the underlying trigger. Patchy, well-circumscribed bald spots point toward alopecia areata, an autoimmune condition with its own treatment pathway. Scalp pain, burning, redness, scaling, or visible scarring suggests a scarring alopecia (lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia), and these require prompt diagnosis because destroyed follicles don’t come back (Kassira et al., JAAD, 2017).
Women with hair loss plus irregular periods, acne, or hirsutism need endocrine evaluation for PCOS or other androgen excess states. Young men progressing more than one Norwood stage per year warrant early, aggressive intervention planning. And anyone who has used standard medical therapy for 12 months without response should be reassessed.
The AAD’s position is simple: any progressive hair loss that concerns the patient is a legitimate reason for consultation.
FAQs
Are hair transplants permanent? Transplanted follicles come from the genetically resistant donor zone and generally maintain their resistance to miniaturization long-term. But surrounding native hair may continue to thin, which is why most transplant patients continue medical therapy afterward.
Is hair loss covered by insurance? Pattern hair loss treatment is classified as cosmetic by most insurers and is not covered. Some HSA and FSA accounts will cover prescribed medications and physician visits.
Is finasteride safe? Finasteride is FDA-approved at 1 mg daily for pattern hair loss and has over two decades of safety data. Sexual side effects occur in a small percentage of users in randomized trials and are generally reversible on discontinuation. This is a conversation to have with a prescribing clinician, not to resolve via internet debate.
Can diet alone slow hair loss? Diet can address contributing factors like iron deficiency or telogen effluvium from severe caloric restriction. It cannot stop the underlying genetic process of androgenetic alopecia.
How accurate are AI hair-loss assessment tools? They provide reasonable orientation for self-screening but do not replace a clinical evaluation. Think of them as triage, not diagnosis.
How fast does pattern hair loss progress? Wildly variable. Some men move one Norwood stage every few years; others remain stable for long stretches. Age of onset, family history, and recent rate of change are the strongest predictors.
Does wearing hats cause hair loss? No. This is one of the most persistent myths in hair loss. Hats do not cause androgenetic alopecia. Extremely tight headwear worn constantly could theoretically contribute to traction alopecia, but that’s a different condition and an extreme scenario.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
